Your browser doesn't support javascript.
loading
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
O'Hara, Mark H; O'Reilly, Eileen M; Varadhachary, Gauri; Wolff, Robert A; Wainberg, Zev A; Ko, Andrew H; Fisher, George; Rahma, Osama; Lyman, Jaclyn P; Cabanski, Christopher R; Mick, Rosemarie; Gherardini, Pier Federico; Kitch, Lacey J; Xu, Jingying; Samuel, Theresa; Karakunnel, Joyson; Fairchild, Justin; Bucktrout, Samantha; LaVallee, Theresa M; Selinsky, Cheryl; Till, Jacob E; Carpenter, Erica L; Alanio, Cécile; Byrne, Katelyn T; Chen, Richard O; Trifan, Ovid C; Dugan, Ute; Horak, Christine; Hubbard-Lucey, Vanessa M; Wherry, E John; Ibrahim, Ramy; Vonderheide, Robert H.
Afiliación
  • O'Hara MH; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • O'Reilly EM; Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Varadhachary G; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA.
  • Wolff RA; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA.
  • Wainberg ZA; Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Ko AH; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Fisher G; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
  • Rahma O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Lyman JP; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Cabanski CR; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Mick R; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Gherardini PF; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Kitch LJ; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Xu J; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Samuel T; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Karakunnel J; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Fairchild J; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Bucktrout S; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • LaVallee TM; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Selinsky C; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Till JE; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Carpenter EL; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Alanio C; Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, U
  • Byrne KT; Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Chen RO; Personalis, Menlo Park, CA, USA.
  • Trifan OC; Apexigen, San Carlos, CA, USA.
  • Dugan U; Bristol Myers Squibb, New York, NY, USA.
  • Horak C; Bristol Myers Squibb, New York, NY, USA.
  • Hubbard-Lucey VM; Cancer Research Institute, New York, NY, USA.
  • Wherry EJ; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology, Perelman Scho
  • Ibrahim R; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Vonderheide RH; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology, Perelman Scho
Lancet Oncol ; 22(1): 118-131, 2021 01.
Article en En | MEDLINE | ID: mdl-33387490
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Paclitaxel / Antígenos CD40 / Desoxicitidina / Albúminas / Nivolumab Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Paclitaxel / Antígenos CD40 / Desoxicitidina / Albúminas / Nivolumab Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos